Compare Summit Therapeutics Inc (SMMT) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Summit Therapeutics Inc trades at $17.55 (market cap $13.79B), while YieldMax TSLA Option Income Strategy ETF trades at $22.52. The key difference: Summit Therapeutics Inc is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| SMMT | TSLY | |
|---|---|---|
Market Cap | $13.79B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $26.38 | $48.25 |
52-Week Low | $12.43 | $20.49 |
Enterprise Value | $13.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
TSLY trades at $22.79, up 3.17% with a bullish technical signal despite bearish moving averages. The ETF maintains consistent weekly dividend distributions ranging from $0.18 to $0.28, though recent analysis highlights concerns about underperformance relative to Tesla's underlying stock. Technical indicators show neutral oscillators with RSI at 59.70, while support and resistance cluster around $22-$24 levels.
The outlook remains mixed with high yield appeal offset by structural limitations in capturing Tesla's upside. Key risks include volatility dependency and capped growth potential. Investors face the trade-off between income generation and capital appreciation in this option-income strategy ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
